anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: With an ageing population, the use of mobility scooters by community-dwelling older adults with mobility limitations has been increasingly prevalent in Singapore. Their experiences in using mobility scooters remain unclear. This study aimed to explore the impact of mobility scooters on occupational performance and engagement among elderly Singaporeans.
MATERIALS AND METHODS: Mobility scooter users were recruited via purposive and snowballing sampling. Semi-structured interviews were conducted in English or Mandarin via phone call or face-to-face and audio-recorded with permission. Interviews were transcribed verbatim in their original language and translated to English (when applicable) for thematic analysis.
RESULTS: Twelve eligible participants (mean age: 75 years) completed the interviews. They were predominantly female Chinese with 7 receiving training from occupational therapists (OT). Four main themes emerged from the interviews describing their experiences of using mobility scooters: factors of decision-making in getting a mobility scooter, enhanced occupational participation with the use of the mobility scooter, enablers for community participation and barriers to community participation. Despite having barriers, older adults with mobility limitations generally still had positive experiences to continue using mobility scooters to perform occupations in the community.
CONCLUSIONS: This study highlights the benefits of mobility scooters in supporting users' occupational performance and engagement in the community. Continual efforts are required from all stakeholders to provide an accessible environment and improve societal attitudes to further support the mobility scooter users.IMPLICATIONS FOR REHABILITATIONMobility scooter users can be deterred from performing their preferred occupations if they had a prior negative encounter and they mainly rely on self-developed coping strategies to overcome possible barriers in the community.Occupational therapists should identify and address the potential barriers when prescribing mobility scooters to older adult users.Occupational therapists should work collaboratively with other key stakeholders, such as external vendors and government agencies, to co-create a universal guideline to support and safeguard mobility scooter users.
<P>PROBLEM TO BE SOLVED: To provide a stent which can convey a useful medicament having a comparatively large volume to a section, which gets a wound, within a blood vessel cavity without increasing the effective wall thickness of the stent and having a bad influence upon the mechanical expansion characteristic of the stent.  <P>SOLUTION: The expandable medical instrument 10 has two or more slender struts 18 which are mutually joined together in order to form an approximately cylindrical instrument which can be expanded to a cylinder form having the second diameter from a cylinder form having the first diameter. At least one of the two or more struts include at least one opening at least partially expanded in the thickness direction of the strut. The useful medicament is loaded into the opening of the stent in order to attain kinetics which emits the medicament at necessary time. Alternatively, the useful medicament is loaded into a form composed in order to attain a necessary medicament discharging profile. Various discharging profiles include zero order, pulsation, an increase, a reduction, a sinusoid function, and other discharging profiles.  <P>COPYRIGHT: (C)2009,JPO&INPIT
INTRODUCTION: Transient ischemic attack (TIA) is a frequent neurological emergency which management and definition have changed radically over the last 15 years. However, recent epidemiological studies of TIA are scarce. We report here on the impact of the shift from a time-based to a tissue-based definition of TIA on its incidence and risk of recurrence in a new population-based cohort with a high rate of patients investigated by MRI.
MATERIALS AND METHODS: We prospectively included all TIAs that occurred between May 2017 and May 2021 from the Normandy Stroke Study, a population-based registry using multiple overlapping sources for exhaustive case identification in Caen la Mer area. TIAs were classified as either time-based (symptoms <24 h) or tissue-based (<24 h and no lesion on brain imaging). Attack and incidence rates were calculated, as was the 90-day ischemic stroke rate.
RESULTS: Five hundred and sixty-seven TIAs (549 single patients) were included, with 80.6% having a brain MRI. Four hundred and ten (72.3%) met the definition of tissue-based TIA. The age standardized attack (to the 2013 European population) rate was 39.5 (95% CI 35.7-43.5) and the age-standardized incidence rate (first ever cerebrovascular event) was 29.7 (95% CI 27.3-34.2). The overall recurrent stroke rate at 90 days was 2.7%, with no difference between patients with or without ischemic lesions on MRI.
CONCLUSION: We found that the use of the tissue-based definition of TIA resulted in a 27.5% reduction in incidence as compared to the time-based definition, but had no impact on the 90-day stroke rate. The burden of TIA remains high, and is likely to increase as the population ages.
All participants in this group will have surgery up to 4 weeks after receiving enzalutamide/placebo (sugar pill in the form of 2 softgel capsules) with hormone therapy. A radical prostatectomy (removal of the prostate and any surrounding tissue that the surgeon thinks may be affected by the cancer).
All qualifying patients will have received DSAEK with concurrent cataract extraction and intraocular lens placement. Data collection will occur between 6-18 months post-operation.
Subjects that participated in the AIR2 study, were blinded and did not receive the treatment. Determine if the Sham group of subjects asthma has progressed any different from those subjects treated with BT.
Polycystic ovary syndrome is a common disease that affects 1 out of 16 women. Metabolic and endocrine abnormalities seen in PCOS include insulin resistance, androgen excess and infertility. This study focuses on the insulin resistance aspect because increased insulin resistance leads to premature onset of impaired glucose tolerance or diabetes whereas decreased insulin resistance reduces androgen excess, improves the ovarian function and increases fertility. Although insulin resistance can be treated with insulin-sensitizing drugs, PCOS clinically manifests during adolescence and the long-term safety of the drug-treatment can be a concern. Thus, improving insulin resistance with effective nutritional approaches would be very desirable. Epidemiological studies and animal experiments suggest that replacement of dietary saturated fats with monounsaturated (MUFA) and polyunsaturated (PUFA) fats improves insulin resistance.
Abuse and addiction are separate and distinct from physical dependence and tolerance. Abuse is characterized by misuse of the drug for nonmedical purposes, often in combination with other psychoactive substances. Physical dependence is a state of adaptation that is manifested by a specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug and/or administration of an antagonist. Tolerance is a state of adaptation in which exposure to a drug induces changes that result in a diminution of one or more of the drug’s effects over time. Tolerance may occur to both the desired and undesired effects of drugs and may develop at different rates for different effects. 

Addiction is a primary, chronic, neurobiological disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.

In a study of abuse liability conducted in individuals with known histories of benzodiazepine abuse, eszopiclone at doses of 6 and 12 mg produced euphoric effects similar to those of diazepam 20 mg. In this study, at doses 2-fold or greater than the maximum recommended doses, a dose-related increase in reports of amnesia and hallucinations was observed for both eszopiclone and diazepam.
OBJECTIVES: Congenital Factor 13 Deficiency (FXIIID) is a rare bleeding disorder (RBD) of autosomal recessive inheritance, with an incidence of 1 in 3-5 million. The clinical symptomatology, diagnosis, and management of FXIIID are described.
METHODS: A retrospective chart review of children with FXIIID was performed from January 2000 through October 2021 at a tertiary care center in Southern India. The diagnosis was performed by the Urea clot solubility test (UCST) and Factor XIII antigen assay.
RESULTS: Twenty children (representing 16 families) were included. Male: Female ratio was 1.5:1. The median age of symptom onset was 6 mo, and the median age of diagnosis was 1 y, demonstrating a delay in diagnosis. Consanguinity was present in 15 (75%) with 4 children having affected siblings. Clinical symptomatology ranged from mucosal bleeds to intracranial bleeds and hemarthrosis, with many children having a history of prolonged umbilical bleeding in their neonatal period. Fourteen children were on cryoprecipitate prophylaxis. Four children had breakthrough bleeds due to irregular prophylaxis, including one intracranial bleed due to a delay in cryoprecipitate prophylaxis during the covid pandemic.
CONCLUSIONS: Congenital FXIIID presents with a wide range of bleeding manifestations. The high prevalence of consanguinity in Southern India can be a cause of FXIIID's high prevalence in this region. There is a propensity for intracranial bleeding with a significant number having this at first presentation. Regular prophylaxis is required and feasible to prevent potentially fatal bleeds.
At birth, the weight and length of children with CHD are close to normal and APGAR scores are generally high. Cyanotic patients are affected in growth, depending on the severity of tissue hypoxemia and on the degree of physiological variation. Mostly acute malnutrition occurs in a cyanotic heart disease but chronic malnutrition occurs in cyanotic lesions. The severity of malnutrition variety from mild under nutrition to failure to thrive. impairing growth and increasing post-operative morbidity and mortality. Early rapid growth retardation detection in early age and improved nutritional status have the potential to reduce cardiac impact on growth and feeding. Insure appropriate nutrition in those patients by the two main methods (enteral and parenteral) help in better outcome
Human fetal development has been associated with brain health at later stages. It is unknown whether growth in utero, as indexed by birth weight (BW), relates consistently to lifespan brain characteristics and changes, and to what extent these influences are of a genetic or environmental nature. Here we show remarkably stable and lifelong positive associations between BW and cortical surface area and volume across and within developmental, aging and lifespan longitudinal samples (N = 5794, 4-82 y of age, w/386 monozygotic twins, followed for up to 8.3 y w/12,088 brain MRIs). In contrast, no consistent effect of BW on brain changes was observed. Partly environmental effects were indicated by analysis of twin BW discordance. In conclusion, the influence of prenatal growth on cortical topography is stable and reliable through the lifespan. This early-life factor appears to influence the brain by association of brain reserve, rather than brain maintenance. Thus, fetal influences appear omnipresent in the spacetime of the human brain throughout the human lifespan. Optimizing fetal growth may increase brain reserve for life, also in aging.
Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA).
The study group is the hematlogic malignant patients that older than 55years and/or with severe concurrent medical conditions, who will undergo HLA-matced allogenic HSCT to cure the disease. The patients will received a modified BuFlu conditioning.
Carbamazepine has shown mild anticholinergic activity that may be associated with increased intraocular pressure; therefore, patients with increased intraocular pressure should be closely observed during therapy.

Because of the relationship of the drug to other tricyclic compounds, the possibility of activation of a latent psychosis and, in elderly patients, of confusion or agitation should be borne in mind.

The use of carbamazepine should be avoided in patients with a history of hepatic porphyria (e.g., acute intermittent porphyria, variegate porphyria, porphyria cutanea tarda). Acute attacks have been reported in such patients receiving carbamazepine therapy. Carbamazepine administration has also been demonstrated to increase porphyrin precursors in rodents, a presumed mechanism for the induction of acute attacks of porphyria.

As with all antiepileptic drugs, carbamazepine should be withdrawn gradually to minimize the potential of increased seizure frequency.   
Hyponatremia can occur as a result of treatment with carbamazepine. In many cases, the hyponatremia appears to be caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The risk of developing SIADH with carbamazepine treatment appears to be dose-related. Elderly patients and patients treated with diuretics are at greater risk of developing hyponatremia. Signs and symptoms of hyponatremia include headache, new or increased seizure frequency, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Consider discontinuing carbamazepine in patients with symptomatic hyponatremia.
PURPOSE: To provide a treating agent of a nicotine type compd. which contains a specific cytisine compd. and is suitable for treatment of a degeneration disease and more particularly treatment of a disease which induces a cholinomimetic defect. CONSTITUTION: This treating agent contains an effective amt. of the compd. (more particularly cuytisine) of the formula (R, R' are substituents exclusive of H, more particularly a 1 to 7C alkyl; R" is H, substituents exclusive of H, more particularly a 1 to 7C alkyl; X is a halo, alkoxy, alkyl; m is 0 to 3; n is 0 to 8; p is 0 to 2). This treating agent is effective for the nerve degeneration disease, such as senile dementia of Alzheimer type in particular, and Perkinson's disease. As the effective amt. of the compd. of the formula is 5 μg and below 150 μg per 1 kg patient's body weight, the treating agent is recommended to be dosed to the patent at 0.10 mg and below 10 mg per hour per patient.  This treating agent is the nicotine type compd. and enhances the number of a nicotine type chohinomimetic acceptor of patient's brain and has potential to indicate the effect of the nerve protection.
Volunteers will provide a urine sample. They will receive 7 tablets of regular-strength aspirin (325 mg) and be instructed to take one tablet daily for 7 days. On the seventh day, they return to have blood drawn, urine collected, and receive niacin as described in arm 1.
FIELD: medicine. ^ SUBSTANCE: invention relates to chemical-pharmaceutical industry and deals with obtaining solution for prevention of commissure-formation and creation of method of commissure-formation prevention, applicable in general surgery, in which covered state during surgical intervention is stable and acceptable. Claimed invention represents solution for preventuion of commissure-formation, in which active ingredient is trehalose. In addition, it contains at least one or more means from the following list: antioxidants, chelates, antiseptics, haemostatics, anti-inflammatory preparations, and polysaccharides, mucopolysaccharides, salts of polysaccharides and salts of mucopolysaccharides, which have lubricating properties. Said solution of commissure-formation prevention is presented in any of the following forms: liquid for perfusion, spray, solution for application in form of spraying or evaporation, foam-like aerosol preparation, solution for injection of intravenous liquids, liquid for intravenous introduction. ^ EFFECT: solution ensures prevention of injury of organs and tissues during operation. ^ 20 cl, 3 ex, 2 tbl
In dose-escalation Cohort 2A, DKN-01 dose level will start with 300 mg and be escalated to 600 mg or de-escalated to 150 mg depending on the absence or presence of identified DLTs. DKN-01 will be administered as monotherapy on Days 1 and 15 of each 28-day cycle. Patients will be treated with DKN-01 until PCWG3 progression or unacceptable toxicity.
The present invention relates to the field of organ transplantation. More specifically, the present invention provides methods for predicting organ function after transplantation. In certain embodiments, the method comprises measuring mitochondrial membrane potential from a biopsy sample from the donor organ. The present invention is also applicable to organ dysfunction in general. More specifically, the methods of the present invention may be useful in formulating prognoses for patients with acute or chronic organ dysfunction due to ischemia, infection, drug injury or age. In this rapid procedure, only small samples of tissue are required, enabling the clinical application of mitochondrial function previously thought impractical.
Participants receive enlicitide chloride titrated orally from Dose 1, Dose 2, or Dose 3 once daily (QD) over the course of a 14-day treatment for each dose based on the safety and tolerability of the previous starting dose. The total treatment duration is up to approximately 6 weeks.
The invention discloses a Chinese medicinal composition for treating cardiovascular disease. The composition is mainly prepared from Salvia miltiorrhiza, Borneo or Dalbergia odoriferous oil or styrax or musk or musk ketone as raw material; also can further comprises Angelica sinensis or Herba Leonuri or further step comprises Astragalus membranaceus or ginseng or radix codonopsis. Its processing steps comprises preparing Salvia miltiorrhiza into water extract or alcohol extract or preparing Salvia miltiorrhiza and Angelica sinensis or Herba Leonuri or Salvia miltiorrhiza and Astragalus membranaceus or ginseng or radix codonopsis pilosulae into water extract or alcohol extract respectively or together, performing primary clarification, performing ultra filtration treatment, concentrating, and mixing with Borneo or Dalbergia odoriferous oil or styrax or musk or musk ketone. The invention also discloses a preparation with any of the aforesaid Chinese medicinal composition as effective ingredient, preferably dripping pill. Its dripping pill substrate adjuvant can be polyethylene glycol or plant original substrate adjuvant. Inventive medicament has rapid action, and good therapeutic action in treating angina pectoris of coronary heart disease.
BACKGROUND: The relationship between sarcopenia and insulin resistance (IR) has seldom been reported. Triglyceride-glucose (TyG) index, a new IR indicator, has gained traction as a prognostic tool for many diseases. We aimed to investigate whether the level of TyG index was related to the incidence of sarcopenia.
METHOD: A total of 1819 participants above 60 without sarcopenia at baseline were included from the China Health and Retirement Longitudinal Study (CHARLS). Cox models were applied to evaluate the association between TyG and incident sarcopenia. Mediation analyses were performed to evaluate the contribution of the level of BMI to observed associations.
RESULTS: During a median follow-up of 4.0 years, 217 (11.9 %) participants developed sarcopenia. The multivariable-adjusted hazard ratios of total sarcopenia in higher quartiles of TyG index versus the lowest quartiles were 0.59, 0.61, and 0.46, respectively. There were significant trends toward a decreasing risk of sarcopenia across the quartiles of TyG index before adjusting for BMI, but no significant association was observed after accounting for BMI. The area under the ROC curve was 0.6281 (0.597-0.660). In subgroup analysis, there was an inverse significant association between TyG index and sarcopenia among male participants. In mediation analyses, BMI explained 88.7 % of the association of TyG index and sarcopenia.
CONCLUSIONS: Our findings indicated that TyG index was negatively associated with incident sarcopenia in older Chinese without considering BMI adjustment. The association was not more significant after adjusting for BMI. BMI mediated the relationship between sarcopenia and TyG index among older Chinese population. Future study should validate our findings in a larger population.
OBJECTIVE: During March 2020, the UK entered a national lockdown, causing a sudden change in undergraduate students' routines. This study uses this event to investigate the impact routine change had on students' mental wellbeing; in particular looking at depression, anxiety, sleep disturbance, and eating behaviors.
METHOD: Participants reported their daily routine timings (waking, breakfast, lunch, evening meal and bedtime) and activities (e.g. exercise amount, time with friends, time studying, etc) on a typical Monday, Wednesday and Saturday during term time and lockdown. Additionally they completed the PROMIS measures of anxiety, depression, and sleep disturbance, and the Eating Pathology Symptom Inventory.
RESULTS: Lockdown saw small but significant shifts in routine timing (on average 1.5 h) However, there was no clear overall pattern of relationships between mental wellbeing and routine structure or magnitude of routine change. There was some evidence of changes in amount of exercise relating to reported anxiety.
DISCUSSION: These findings are consistent with the current literature reporting lockdown effects on behavior. Routine timings shifted, but this change was small and largely did not affect the mental wellbeing reported by undergraduate students. The change in amount of exercise posed by lockdown did appear to be an important factor in wellbeing, and more research should focus on the wellbeing implications of closing places for exercise.
The proposed study will consist of a double-blinded, randomized controlled trial using a crossover design to assess the effects of SSRIs (escitalopram oxalate, Lexapro®, Forest Pharmaceuticals, Inc) and 5HT-antagonists (cyproheptadine \[CYPRO\], Periactin ®, Merck, Inc) on volitional and spastic motor behaviors in subjects with motor incomplete SCI following both acute and chronic medication delivery. Voluntary and reflexive motor behaviors in 120 subjects with SCI will be assessed. These interventions will be applied to individuals with acute (\< 6 months post injury) chronic (\> 1 year post injury) motor incomplete SCI to determine both the rate and extent of changes in volitional motor performance and involuntary spastic behaviors. For the training portion of the study (referred to as subproject 2 below), a portion of the acute and chronic subjects will be evaluated every 2 weeks for up to16 weeks and participate in locomotor training, to investigate and better understand changes in motor function and recovery in individuals with spinal cord injuries. Following 2-4 weeks of this training, individuals will be given either the study drug, or placebo and continue evaluation and training. Following an additional 4 weeks, subjects will be given either the placebo or study drug (whichever they did not receive during the prior 4 weeks). The order will be randomized.
Dosing will occur in two phases - induction and maintenance. During induction, the subject will receive Abraxane plus carboplatin as standard of care. At the end of 4 cycles, if the subject has a complete response, partial response, or stable disease, he/she will continue on to the maintenance phase. Maintenance dosing on this arm includes Abraxane plus best supportive care.